Shares of BioMS Medical Corp (MS.TO: Quote) plunged 90 percent on Tuesday after the company and Eli Lilly and Co (LLY.N: Quote) said their multiple sclerosis treatment failed to delay the progression of the disease in a late-stage trial.
A revolutionary surgery that involves drilling a hole in the skull and injecting cells could repair some devastating effects of multiple sclerosis.
Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
Created especially for the public, SearchClinicalTrials.org allows you to search multiple websites for clinical trial listings, results, and publications at one time. Search by Disease or Condition, Location, Sponsor, Age, Phase, and much more.
Serono announced today the initiation of a Phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of Rebif(R) (interferon beta-1a 44 mcg, three times a week or once a week) on the time to
The Roskamp Institute announced today its participation in a pharmaceutical sponsored research study for relapsing-remitting Multiple Sclerosis (MS) sufferers.
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurol
The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions observed on serial MRI scans of the brain at weeks 12, 16, 20 and 24 in the Rituxan-treated group compared to placebo
This study will evaluate the long-term safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis. Evaluation in larger, longer-term studies is warranted.
Data analyzed after two years showed a 75 percent reduction in the risk of relapse for patients taking Campath compared to patients treated with Rebif, Genzyme says.
Biotechnology companies Genentech Inc. and Biogen Idec Inc. on Monday said their cancer drug Rituxan showed hints of effectiveness against multiple sclerosis in a small mid-stage trial
The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of R-R MS.
Teva Pharmaceutical Industries Ltd. announced the initiation of a large Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA) to the currently approve
